---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-022575"
form_type: "8-K"
ticker: "RGBP"
cik: "0001589150"
company_name: "Regen BioPharma Inc"
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:35:48.298008+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Regen Biopharma issues $100K convertible note to Labrys Fund at 60% discount conversion

## Summary
- Principal $100,000; net proceeds $85,000 after $15,000 original issue discount.
- 6% interest per annum; maturity date August 5, 2026.
- Conversion price is 60% of lowest trading price over prior 20 trading days.
- Beneficial ownership limitation set at 4.99% (can be increased to 9.99% by holder).
- Shares upon conversion are unregistered and subject to restrictive legend.

## SEC filing metadata
- accession: 0001641172-25-022575
- form_type: 8-K
- ticker: RGBP
- cik: 0001589150
- company_name: Regen BioPharma Inc
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1589150/000164117225022575/0001641172-25-022575-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1589150/000164117225022575/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-022575
- JSON: https://secwatch.observer/filing/0001641172-25-022575.json
- Plain text: https://secwatch.observer/filing/0001641172-25-022575.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.